用于血管事件的二次预防的素:对试验的元分析

Marc-André d'Entremont^1,2,3, Michiel H F Poorthuis⁴, Aernoud T L Fiolet^5,6

¹Population Health Research Institute, 237 Barton Street East, Hamilton L8L 2X2, Ontario, Canada.

European heart journal

|May 2, 2025

概括

在患有冠状动脉疾病或中风的患者中,素显著降低了主要的心血管事件. 这项对9项试验的分析证实了其在二次预防中的益处,尽管胃肠道事件的风险更高.

科学领域:

心脏病学心脏病学
药理学药理学是指药理学的学科.
临床试验临床试验

背景情况:

动脉样性心血管疾病 (ASCVD) 的二次预防仍然是一个关键的临床挑战.
之前的随机试验中,用于ASCVD二次预防的菌素已经产生了不一致的结果.
了解菌素在ASCVD管理中的确切作用需要强有力的证据综合.

研究的目的:

进行随机对照试验 (RCT) 的系统审查和元分析.
为了评估与安慰剂相比,在患有已确定的ASCVD的患者中,结石素的疗效和安全性.
确定胆固醇对主要心血管不良事件 (MACE) 和安全结果的影响.

主要方法:

对RCT进行系统审查和研究水平的元分析.
包含的试验比较了二次预防ASCVD人群中的黄素与没有黄素.
使用固定效应逆方差模型与治疗意图数据.

主要成果:

分析了9项试验,包括30,659名患者 (15,255名接受了素治疗).
胆固醇降低了心血管死亡,心肌梗塞或中风的综合结果 (RR 0.88,P=.002).
对心肌梗塞 (RR 0.84,P=.016) 观察到具体的减少,对于中风 (RR 0.90,P=.09) 有趋势. 胆固醇增加了胃肠道事件住院 (RR 1.35,P=.004),但不是肺炎,癌症或非CV死亡.

结论:

在之前患有冠状动脉疾病或中风的患者中,氨酸显示了复合MACE的显著12%降低.
减少心肌梗塞的好处是显著的.
虽然有效,但潜在的胃肠道副作用在临床实践中需要考虑.

关键词:

科尔奇辛 (Colchicine) 是一种可口药.冠状动脉复血管化治疗炎症炎症是一种炎症.心肌梗塞的心脏病发作一次性中风,中风.

相关概念视频

01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

388

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

388

01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

991

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

991

01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

536

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

536

01:15

Drugs that Stabilize Microtubules

1.9K

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

1.9K

01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

385

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

385

01:22

Alzheimer's Disease: Treatment

128

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

128